Q-omics provides the consensus-scored BUB1B-PAK6 profile across patient tissues and cancer cell-line models. BUB1B-PAK6 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BUB1B-PAK6 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, BUB1B-PAK6 RNA expression shows 12,128 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where BUB1B-PAK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BUB1B-PAK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BUB1B-PAK6 survival associations across molecular data types. BUB1B-PAK6 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BUB1B-PAK6 RNA expression–survival associations across cancer types. High BUB1B-PAK6 expression shows unfavorable associations in COAD, BRCA, MESO, SKCM and KIRP, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BUB1B-PAK6 RNA expression.
This table summarizes BUB1B-PAK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BUB1B-PAK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BUB1B-PAK6 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LUSC, READ, LUAD and COAD. The KIRC box plot shows higher BUB1B-PAK6 RNA expression in normal versus tumor tissue (log2 FC = −0.016, t-test p < 0.001).
This table shows molecular features associated with BUB1B-PAK6 in patient tissues and cancer cell lines. In patient samples, BUB1B-PAK6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
